Harvey M. Golomb, MD

home / authors / harvey-m-golomb-md

Articles

Doublets and Triplets: New Drug Combinations in the Palliative Care of NSCLC

Everett E. Vokes, MD;Gregory A. Masters, MD;Harvey M. Golomb, MD;Philip C. Hoffman, MD

October 2nd 1997

Chemotherapy has been shown to prolong survival in patients with stage IV non-small-cell lung cancer (NSCLC). However, traditional cisplatin (Platinol)-containing regimens are associated with significant toxicity.

Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies

Gregory A. Masters, MD;Stuart A. Krauss, MD;Harvey M. Golomb, MD;Daniel J. Haraf, MD;Philip C. Hoffman, MD;Mark K. Ferguson, MD;Jemi Olak, MD;Everett E. Vokes, MD

October 2nd 1997

Newer chemotherapy drugs have shown encouraging activity in advanced non-small-cell lung cancer. Based on these improved outcomes, as well as the high rate of distant relapse in patients with locally advanced disease, several recent studies have evaluated the use of systemic therapy in patients with earlier-stage disease.

Phase I Study of Docetaxel and Concomitant Chest Radiation

Everett E. Vokes, MD;Ann M. Mauer, MD;Daniel J. Haraf, MD;Gregory A. Masters, MD;Philip C. Hoffman, MD;Harvey M. Golomb, MD;Sylvia Watson, RN

July 1st 1997

Data from the Radiation Therapy Oncology Groupand Eastern Cooperative Oncology Group indicate that increased survival